Difference between revisions of "Team:UFlorida/HP/Silver"

Line 3: Line 3:
 
<div class="column full_size">
 
<div class="column full_size">
  
<h1>Silver Medal Human Practices</h1>
+
 
 
<div class="column full_size">
 
<div class="column full_size">
  
Line 11: Line 11:
 
We also received feedback on our project design from Dr. Anna Savage from the University of Central Florida. Dr. Savage’s research focuses on the immunogenetics and disease ecology of Chytridiomycosis and Batrachochytrium dendrobatidis (Bd). Dr. Savage expressed her concern that we were not appropriately distinguishing between effective antifungal activity against Bd (or another fungus in the Chytridiomycota family) in the lab, and prevention or treatment of the Chytridiomycosis infection in the natural environment. Unfortunately we were not able to receive permissions to test on frogs over the duration of the iGEM competition, but this step would be necessary for future experimental verification that the bacteria are capable of preventing infection in the natural environment. Dr. Savage also suggested that we consider several other secondary metabolite compounds to diversify the antifungal activity of our bacteria and to therefore ensure maximum antifungal against Bd. We did initially consider using violacein in addition to tryptophol, however violacein is a broad antifungal that would ecologically impact natural fungal species other than Bd. We struggled to find another antifungal compound that would have a minimal impact on the greater ecosystem so we decided to just modify E. coli to produce tryptophol for this project.
 
We also received feedback on our project design from Dr. Anna Savage from the University of Central Florida. Dr. Savage’s research focuses on the immunogenetics and disease ecology of Chytridiomycosis and Batrachochytrium dendrobatidis (Bd). Dr. Savage expressed her concern that we were not appropriately distinguishing between effective antifungal activity against Bd (or another fungus in the Chytridiomycota family) in the lab, and prevention or treatment of the Chytridiomycosis infection in the natural environment. Unfortunately we were not able to receive permissions to test on frogs over the duration of the iGEM competition, but this step would be necessary for future experimental verification that the bacteria are capable of preventing infection in the natural environment. Dr. Savage also suggested that we consider several other secondary metabolite compounds to diversify the antifungal activity of our bacteria and to therefore ensure maximum antifungal against Bd. We did initially consider using violacein in addition to tryptophol, however violacein is a broad antifungal that would ecologically impact natural fungal species other than Bd. We struggled to find another antifungal compound that would have a minimal impact on the greater ecosystem so we decided to just modify E. coli to produce tryptophol for this project.
 
<br><br>
 
<br><br>
We also started a community dialogue through events with the Florida Museum of Natural History and through presentations to classes at the University of Florida. Our public outreach can be seen here <li><a href="https://2017.igem.org/Team:UFlorida/Engagement">Public Engagement</a></li>
+
We also started a community dialogue through events with the Florida Museum of Natural History and through presentations to classes at the University of Florida. Our public outreach can be seen here:
</div>
+
<li><a href="https://2017.igem.org/Team:UFlorida/Engagement">Public Engagement</a></li>
 
+
<div class="column half_size">
+
<h5>Some Human Practices topic areas </h5>
+
<ul>
+
<li>Philosophy</li>
+
<li>Public Engagement / Dialogue</li>
+
<li>Education</li>
+
<li>Product Design</li>
+
<li>Scale-Up and Deployment Issues</li>
+
<li>Environmental Impact</li>
+
<li>Ethics</li>
+
<li>Safety</li>
+
<li>Security</li>
+
<li>Public Policy</li>
+
<li>Law and Regulation</li>
+
<li>Risk Assessment</li>
+
</ul>
+
</div>
+
 
+
 
+
<div class="column half_size">
+
<h5>What should we write about on this page?</h5>
+
<p>On this page, you should write about the Human Practices topics you considered in your project, and document any special activities you did (such as visiting experts, talking to lawmakers, or doing public engagement). This should include all of the work done for the Silver Medal Criterion #3. Details for your Gold medal work and/or work for the two Human Practices special prizes should be put on those specified pages.</p>
+
</div>
+
 
+
 
+
<div class="column half_size">
+
<h5>Inspiration</h5>
+
<p>Read what other teams have done:</p>
+
<ul>
+
<li><a href="https://2014.igem.org/Team:Dundee/policypractice/experts">2014 Dundee </a></li>
+
<li><a href="https://2014.igem.org/Team:UC_Davis/Policy_Practices_Overview">2014 UC Davis </a></li>
+
<li><a href="https://2013.igem.org/Team:Manchester/HumanPractices">2013 Manchester </a></li>
+
<li><a href="https://2013.igem.org/Team:Cornell/outreach">2013 Cornell </a></li>
+
</ul>
+
 
</div>
 
</div>
  

Revision as of 15:56, 31 October 2017


Silver Medal Human Practices

We met with Dr. Jason Blackburn from the University of Florida to discuss the design of our project. Dr. Blackburn specializes in wildlife disease ecology and is the associate curator of amphibians and reptiles at the Florida Museum of Natural History. Dr. Blackburn was excited to hear about our project. He thought it would be a good idea to work with a singular antifungal compound in order to identify if the isolated bacterial metabolites have therapeutic potential against Chytridiomycosis. Dr. Blackburn pointed out that research has been conducted towards supplementing the amphibian skin microbiome with symbiotic bacteria to prevent the Chytridiomycosis infection. However bacterial metabolites synthesized from modified E. coli have not yet been tested. Dr. Blackburn discussed the potential of producing the bacterial metabolites on a larger scale for use in combating Chytridiomycosis because the bacterial metabolites do not come with the same health hazards that traditional antifungal treatments have for amphibians.

We also received feedback on our project design from Dr. Anna Savage from the University of Central Florida. Dr. Savage’s research focuses on the immunogenetics and disease ecology of Chytridiomycosis and Batrachochytrium dendrobatidis (Bd). Dr. Savage expressed her concern that we were not appropriately distinguishing between effective antifungal activity against Bd (or another fungus in the Chytridiomycota family) in the lab, and prevention or treatment of the Chytridiomycosis infection in the natural environment. Unfortunately we were not able to receive permissions to test on frogs over the duration of the iGEM competition, but this step would be necessary for future experimental verification that the bacteria are capable of preventing infection in the natural environment. Dr. Savage also suggested that we consider several other secondary metabolite compounds to diversify the antifungal activity of our bacteria and to therefore ensure maximum antifungal against Bd. We did initially consider using violacein in addition to tryptophol, however violacein is a broad antifungal that would ecologically impact natural fungal species other than Bd. We struggled to find another antifungal compound that would have a minimal impact on the greater ecosystem so we decided to just modify E. coli to produce tryptophol for this project.

We also started a community dialogue through events with the Florida Museum of Natural History and through presentations to classes at the University of Florida. Our public outreach can be seen here:

  • <a href="https://2017.igem.org/Team:UFlorida/Engagement">Public Engagement</a>

  • </html>